CETN2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09480(CETN2 Antibody) at dilution 1/200. (Original magnification: ×200)    

  
  

The CETN2 antibody targets Centrin-2 (CETN2), a small calcium-binding protein belonging to the centrin family, which is evolutionarily conserved across eukaryotes. CETN2 is primarily localized to centrosomes, basal bodies, and ciliary structures, playing critical roles in centriole duplication, centrosome assembly, and ciliogenesis. It interacts with proteins like XRCC5 (Ku80) to participate in DNA damage repair processes, linking centrosomal functions to genomic stability. CETN2 is also implicated in regulating cell cycle progression, particularly during the G1/S transition and mitotic exit.

Antibodies against CETN2 are widely used in research to study centrosome dynamics, ciliary dysfunction, and mechanisms underlying diseases such as ciliopathies, cancer, and infertility. These antibodies enable techniques like immunofluorescence microscopy to visualize centrosome structure, Western blotting to assess protein expression levels, and immunoprecipitation to explore protein interaction networks. CETN2 expression is often elevated in certain cancers, making it a potential biomarker for tumor progression.

Validation of CETN2 antibodies typically involves knockout cell lines or siRNA-mediated knockdown to confirm specificity. Cross-reactivity with other centrin isoforms (e.g., CETN1 or CETN3) is a consideration during experimental design. Studies using CETN2 antibodies have advanced understanding of how centrosomal abnormalities contribute to microcephaly, retinal degeneration, and other developmental disorders, underscoring its biomedical relevance.